You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Details for Patent: 10,328,029

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,328,029 protect, and when does it expire?

Patent 10,328,029 protects NITYR and is included in one NDA.

This patent has fourteen patent family members in fourteen countries.

Summary for Patent: 10,328,029

Title:	Pharmaceutical composition
Abstract:	The present invention relates to oral pharmaceutical compositions comprising nitisinone, or a pharmaceutically acceptable salt thereof, their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria. The compositions have improved stability characteristics. The invention also relates to processes for producing nitisinone.
Inventor(s):	Harrison; James (Little Shelford, GB), Fuller; Stephen (Cambridge, GB), Brown; Tobias Josef (Cambridge, GB)
Assignee:	CYCLE PHARMACEUTICALS LTD (Cambridge, Cambridgeshire, GB)
Application Number:	15/109,220
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,328,029

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cycle	NITYR	nitisinone	TABLET;ORAL	209449-001	Jul 26, 2017		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE	⤷ Try a Trial
Cycle	NITYR	nitisinone	TABLET;ORAL	209449-002	Jul 26, 2017		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE	⤷ Try a Trial
Cycle	NITYR	nitisinone	TABLET;ORAL	209449-003	Jul 26, 2017		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,328,029

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1400117.6	Jan 3, 2014

PCT Information
PCT Filed	January 05, 2015	PCT Application Number:	PCT/GB2015/050006
PCT Publication Date:	July 09, 2015	PCT Publication Number:	WO2015/101794

International Family Members for US Patent 10,328,029

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2935013	⤷ Try a Trial
Cyprus	1123394	⤷ Try a Trial
Denmark	3089740	⤷ Try a Trial
European Patent Office	3089740	⤷ Try a Trial
Spain	2806739	⤷ Try a Trial
United Kingdom	201400117	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.